HC Wainwright Issues Negative Outlook for Nuvalent Earnings

Nuvalent, Inc. (NASDAQ:NUVL - Free Report) - HC Wainwright reduced their Q1 2025 EPS estimates for shares of Nuvalent in a research note issued on Monday, March 3rd. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($1.21) per share for the quarter, down from their prior estimate of ($1.08). HC Wainwright has a "Buy" rating and a $110.00 price objective on the stock. The consensus estimate for Nuvalent's current full-year earnings is ($3.86) per share. HC Wainwright also issued estimates for Nuvalent's Q2 2025 earnings at ($1.18) EPS, Q3 2025 earnings at ($1.15) EPS, Q4 2025 earnings at ($1.12) EPS, FY2025 earnings at ($4.66) EPS and FY2026 earnings at ($3.26) EPS.

NUVL has been the subject of a number of other research reports. BMO Capital Markets increased their price target on Nuvalent from $132.00 to $134.00 and gave the company an "outperform" rating in a research report on Wednesday, November 13th. Wedbush reiterated an "outperform" rating and issued a $115.00 target price on shares of Nuvalent in a report on Monday, January 13th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $113.10.

Nuvalent Trading Down 2.6 %

Shares of NASDAQ NUVL traded down $1.87 during mid-day trading on Wednesday, reaching $71.07. The company had a trading volume of 473,621 shares, compared to its average volume of 455,730. The company has a 50-day moving average price of $79.32 and a two-hundred day moving average price of $88.35. The stock has a market cap of $5.05 billion, a PE ratio of -20.48 and a beta of 1.42. Nuvalent has a 1-year low of $61.80 and a 1-year high of $113.51.

Remove Ads

Nuvalent (NASDAQ:NUVL - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.03) by ($0.02).

Insiders Place Their Bets

In other news, CEO James Richard Porter sold 27,000 shares of Nuvalent stock in a transaction on Monday, December 16th. The stock was sold at an average price of $86.61, for a total value of $2,338,470.00. Following the completion of the sale, the chief executive officer now directly owns 188,113 shares of the company's stock, valued at approximately $16,292,466.93. This trade represents a 12.55 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Henry E. Pelish sold 2,483 shares of the business's stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $79.68, for a total value of $197,845.44. Following the sale, the insider now directly owns 59,981 shares of the company's stock, valued at $4,779,286.08. This represents a 3.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 110,800 shares of company stock worth $8,895,004 over the last three months. 12.52% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Nuvalent

Several hedge funds have recently added to or reduced their stakes in the stock. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Nuvalent during the fourth quarter valued at approximately $4,428,000. GF Fund Management CO. LTD. bought a new position in shares of Nuvalent during the fourth quarter worth $108,000. Woodline Partners LP grew its holdings in shares of Nuvalent by 0.9% in the 4th quarter. Woodline Partners LP now owns 1,204,927 shares of the company's stock valued at $94,322,000 after buying an additional 11,248 shares during the period. Vestal Point Capital LP bought a new stake in shares of Nuvalent in the 4th quarter valued at $46,968,000. Finally, Soleus Capital Management L.P. raised its stake in Nuvalent by 40.3% during the 4th quarter. Soleus Capital Management L.P. now owns 104,357 shares of the company's stock worth $8,169,000 after buying an additional 30,000 shares during the period. Institutional investors and hedge funds own 97.26% of the company's stock.

Nuvalent Company Profile

Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.